Literature DB >> 28711657

Kaempferol impedes IL-32-induced monocyte-macrophage differentiation.

Sun-Young Nam1, Hyun-Ja Jeong2, Hyung-Min Kim3.   

Abstract

Kaempferol possesses a wide range of therapeutic properties, including antioxidant, anti-inflammatory, and anticancer properties. The present study sought to evaluate the effects and possible pharmacological mechanisms of kaempferol on interleukin (IL)-32-induced monocyte-macrophage differentiation. In this study, we performed flow cytometry assay, immunocytochemical staining, quantitative real-time PCR, enzyme-linked immuno sorbent assay, caspase-1 assay, and Western blotting to observe the effects and underlying mechanisms of kaempferol using the human monocyte cell line THP-1. The flow cytometry, immunocytochemical staining, and real-time PCR results show that kaempferol attenuated IL-32-induced monocyte differentiation to product macrophage-like cells. Kaempferol decreased the production and mRNA expression of pro-inflammatory cytokines, in this case thymic stromal lymphopoietin (TSLP), IL-1β, tumor necrosis factor (TNF)-α, and IL-8. Furthermore, kaempferol inhibited the IL-32-induced activation of p38 and nuclear factor-κB in a dose-dependent manner in THP-1 cells. Kaempferol also ameliorated the lipopolysaccharide-induced production of the inflammatory mediators TSLP, IL-1β, TNF-α, IL-8, and nitric oxide of macrophage-like cells differentiated by IL-32. In brief, our findings may provide new mechanistic insights into the anti-inflammatory effects of kaempferol.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  IL-32; Kaempferol; Macrophage differentiation; Thymic stromal lymphopoietin

Mesh:

Substances:

Year:  2017        PMID: 28711657     DOI: 10.1016/j.cbi.2017.07.010

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  5 in total

1.  [Bushen Huatan recipe for treatment of polycystic ovary syndrome: therapeutic mechanism based on network pharmacology and molecular docking].

Authors:  M Gao; Y Hong; M Cui; J Huang; Y Tan; X Nie
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2022-01-20

2.  A network pharmacology approach to explore active compounds and pharmacological mechanisms of epimedium for treatment of premature ovarian insufficiency.

Authors:  Huishan Zhao; Yinghua Shan; Zhi Ma; Mingwei Yu; Benjiao Gong
Journal:  Drug Des Devel Ther       Date:  2019-08-22       Impact factor: 4.162

Review 3.  Kaempferol as a Dietary Anti-Inflammatory Agent: Current Therapeutic Standing.

Authors:  Waqas Alam; Haroon Khan; Muhammad Ajmal Shah; Omar Cauli; Luciano Saso
Journal:  Molecules       Date:  2020-09-07       Impact factor: 4.411

4.  Comparison of the Seven Interleukin-32 Isoforms' Biological Activities: IL-32θ Possesses the Most Dominant Biological Activity.

Authors:  Saerok Shim; Siyoung Lee; Yasmin Hisham; Sinae Kim; Tam T Nguyen; Afeisha S Taitt; Jihyeong Hwang; Hyunjhung Jhun; Ho-Young Park; Youngmin Lee; Su Cheong Yeom; Sang-Yeob Kim; Yong-Gil Kim; Soohyun Kim
Journal:  Front Immunol       Date:  2022-02-25       Impact factor: 7.561

Review 5.  Immunoceuticals: Harnessing Their Immunomodulatory Potential to Promote Health and Wellness.

Authors:  Sophie Tieu; Armen Charchoglyan; Lauri Wagter-Lesperance; Khalil Karimi; Byram W Bridle; Niel A Karrow; Bonnie A Mallard
Journal:  Nutrients       Date:  2022-09-30       Impact factor: 6.706

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.